School of Medicine
Showing 631-640 of 1,214 Results
-
Kyle Loh
Associate Professor of Developmental Biology (Stem Cell)
BioHow the richly varied cell-types in the human body arise from one embryonic cell is a marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different types of cells. This roadmap allowed us to generate enriched populations of human brain, blood, blood vessel, bone, and other cells in a Petri dish from embryonic stem cells, with implications for developmental biology, stem cell biology, and regenerative medicine. Additionally, we have an emerging interest in exploring deadly biosafety level 4 viruses together with our collaborators.
Kyle attended the County College of Morris and Rutgers, and received his Ph.D. from Stanford (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute for Talent Development. He then continued as a Siebel Investigator, and later, as an faculty member at Stanford. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar. His research has been recognized by the NIH Director's Early Independence Award, ISSCR Early Career Impact Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship. -
Adrienne H. Long, MD, PhD
Instructor, Pediatrics - Hematology & Oncology
BioAdrienne H. Long, MD, PhD is an Instructor and Physician-Scientist in the Division of Pediatric Hematology and Oncology at the Lucile Packard Children's Hospital, Stanford. Clinically, she completed her MD at Northwestern University, her pediatrics residency at Boston Children’s Hospital, and her oncology fellowship training at Stanford University. Dr. Long sees patients with leukemias/lymphomas, and has a clinical interest in T cell malignancies.
Dr. Long received her PhD in Microbiology/Immunology through a National Institutes of Health (NIH) – Northwestern University partnership, where she worked with Dr. Crystall Mackall to advance CAR T cell therapies. Her influential thesis work was the first to identify T cell exhaustion as a critical factor limiting efficacy of CAR therapies (Long et al., Nature Medicine, 2015). She continued her research training with Dr. Nicholas Haining at the Dana Farber Cancer Institute during residency and is currently conducting her post-doctoral research with Dr. Mark Davis at Stanford.
Dr. Long’s research interests lie at the intersection of the immune system and cancer therapies. She is currently studying how thymic selection, designed to prevent auto-immunity, may also inhibit anti-tumor immunity in children. She is also interested in how immunotherapies that have revolutionized how we treat cancer can impact the developing pediatric immune system long term. -
Jonathan Z. Long
Associate Professor of Pathology
BioDr. Jonathan Long is an Associate Professor of Pathology and an Institute Scholar of Stanford ChEM-H (Chemistry, Engineering & Medicine for Human Health). His laboratory studies the molecular mechanisms of mammalian energy homeostasis. Dr. Long is the recipient of the Alfred P. Sloan Research Fellowship in Chemistry, the Breakthrough Sciences Award from the Ono Pharma Foundation, and the NIDDK Catalyst Award. Prior to arriving to Stanford, Dr. Long completed his Ph.D. in Chemistry at Scripps Research and his postdoctoral work at Harvard Medical School.
-
Dr. Michael T. Longaker
Deane P. and Louise Mitchell Professor in the School of Medicine and Professor, by courtesy, of Materials Science and Engineering
Current Research and Scholarly InterestsWe have six main areas of current interest: 1) Cranial Suture Developmental Biology, 2) Distraction Osteogenesis, 3) Fibroblast heterogeneity and fibrosis repair, 4) Scarless Fetal Wound Healing, 5) Skeletal Stem Cells, 6) Novel Gene and Stem Cell Therapeutic Approaches.
-
Billy W Loo Jr, MD PhD FASTRO FACR
Professor of Radiation Oncology (Radiation Therapy)
Current Research and Scholarly InterestsMy clinical specialty is precision targeted radiotherapy of thoracic cancers.
My research is on developing next-generation ultra-rapid radiotherapy technology (PHASER) and studying the radiobiological effects of FLASH treatment.
My clinical research is on advanced 4-D image-guided radiotherapy and stereotactic ablative radiotherapy (SABR), and functional and metabolic imaging and imaging biomarkers. -
Alarice Cheng-Yi Lowe
Associate Professor of Pathology
BioDr. Lowe joined the School of Medicine faculty in 2019. She received her undergraduate degree in Biology from MIT and her medical degree at UCSD, prior to residency and cytology fellowship at UCLA. In 2011, she joined the faculty at Brigham and Women's Hospital where she developed a research focus on Circulating Tumor Cells (CTCs) and the application of new technology to improve clinical and molecular diagnostics. Clinically, her interests focus on Cytopathology and Genitourinary Pathology.
-
Lu,Guolan
Assistant Professor of Urology
Current Research and Scholarly InterestsThe Lu Lab develops and integrates AI, spatial multi-omics, and advanced imaging to understand and model how cells, tissues, and therapeutic agents interact in their native spatial context, and how these interactions drive disease progression and treatment response.
-
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.
As a physician, Sydney’s group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of ‘wet-lab’ and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.
Sydney’s research is/has been supposed by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute.
